April 2015

Treatment of recurrent refractory mantle cell lymphoma by thalidomide in combination with interferon

Mantle cell lymphoma (MCL) is a highly aggressive non-Hodgkin's lymphoma with poor prognosis. This study aims to explore a new, safe approach for patients with recurrent refractory MCL. A total of six patients with recurrent refractory MCL were recruited. They all accepted thalidomide tablets (100 mg/day) orally every night, accompanied with interferon α-2b (3 million units, injected subcutaneously) every...

Author(s): Lijie Han, Huifang Zhao, Qingsong Yin, Lin Chen, Yongping Song and Xudong Wei